VistaGen Therapeutics Inc (VTGN NASDAQ) stock market data APIs

$2.0192 0.09(4.5%)
as of June 20, 2025
Try our APIs with free plan!

VistaGen Therapeutics Inc Financial Data Overview

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Prev. Close 2.0192
Open 2.1044
High 2.2077
Low 2.0192
52 wk Range 1.9-4.21
Market Cap 59 456 K
Shares Outstanding 28 862 K
Revenue 486 K
EPS -0.44
Beta 0.687

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get VistaGen Therapeutics Inc data using free add-ons & libraries


Get VistaGen Therapeutics Inc Fundamental Data

VistaGen Therapeutics Inc Fundamental data includes:

  • Net Revenue: 486 K
  • EBITDA: -55 823 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get VistaGen Therapeutics Inc Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2025-03-31
  • EPS/Forecast: -0.49
GET THE PACKAGE

Get VistaGen Therapeutics Inc End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

VistaGen Therapeutics Inc News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat